Pullan's Pieces

BACK ISSUES of PULLAN'S PIECES 

March 2025- Pullan's Pieces #212
Linda: Big pharma deals in 2025?
Linda:  Big pharma unprecedented targets in CV, CNS, metabolic
Kristine:  ADC Trends
Trevor:  Soft landing optimism

February 2025 - Pullan's Pieces #211
Linda: Rare disease landscape
Linda:  RNA binding proteins
Kristine:  China Biotech
Trevor:  The money-spending business

January 2025 - Pullan's Pieces #210
Linda:  Amgen- an evolving company
Kristine:  Anti-PD1xVEGF opportunity
Trevor:  Seed to series A

November 2024 - Pullan's Pieces #209
Linda: Big Pharma Immunology in Preclinical and Discovery
Linda:  Deals are down! 
Kristine:  Obesity therapeutics
Trevor:  XBI better than S&P
 
October 2024 - Pullan's Pieces #208
Linda:  The Pfizer Activist Challenge
Linda:  How competitive is partnering your drug?
Kristine:  Investing in Private Biotechs
Trevor:  Betting on everything

September 2024 - Pullan's Pieces #207
Linda: Where are the drugs?
Linda:  China snapshot
Kristine:  Novel targets in Alzheimer's and Parkinson's
Trevor:  Rate cut and XBI falls

August 2024- Pullan's Pieces #206
Linda: Early-stage fund-raising remains hard
Linda:  Licensing and M&A uneven
Kristine:  The IRA and Orphan Drugs
Trevor:  More optimism?

July 2024- Pullan's Pieces #205
Linda: Where are the sales?
Linda:  Your BATNA  
Kristine:  Pharma Option and License Deals
Trevor:  Head and Shoulders?

June 2024- Pullan's Pieces #204
Linda: MASH- the old NASH is newly exciting
Linda:  Gilead - a snapshot  
Kristine:  M&A:  What does Pharma want?
Trevor:  Market Sentiment:  On more solid footing..

May 2024- Pullan's Pieces #203
Linda: IPOs of 2024
Linda:  Market cap per employee and other stats by territory  
Kristine:  Option Deals in Biotech
Trevor:  Market Sentiment:  Marking Time?

​​a free monthly email newsletter with analysis relating to biotech and pharmaceutical deals and trends.  


Click on the months below for a few samples and sign up here